New Delhi [India], August 13 (ANI): In order to strengthen the fight of the States and Union Territories against the COVID-19 pandemic, the Union Cabinet has released 50 per cent funds of the 'India COVID-19 Emergency Response & Health System Preparedness Package: Phase-II (ECRP-II packa
Greater Noida (Uttar Pradesh) [India], July 30 (ANI/NewsVoir): Migsun Group, one of the leading real estate developers in Delhi/NCR, announced that it had received the Completion Certificate for 672 units in Phase I of Migsun Wynne before the RERA stipulated time. The project, which is adjac
Hyderabad (Telangana) [India], July 21 (ANI/PNN): Optimus Pharma on Sunday submitted the interim result of Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild Covid-19 patients.
New Delhi [India], July 15 (ANI): Union Health Ministry on Thursday asked states and Union Territories (UTs) to conduct a quick gap analysis for various infrastructure components under the "India COVID-19 Emergency Response and Health Systems Preparedness Package: Phase II" and stressed on e
Hyderabad (Telangana) [India], July 9 (ANI): Hetero, a globally renowned vertically integrated pharmaceutical organization, on Friday announced the interim clinical results from Phase III clinical trials of Molnupiravir in mild Covid-19 patients conducted across multiple COVID-19 dedicated h
New Delhi [India], July 8 (ANI): The Union Cabinet chaired by Prime Minister Narendra Modi has approved a new scheme 'India COVID-19 Emergency Response & Health System Preparedness Package: Phase-II' amounting to Rs 23,123 crore for FY 2021-22.
New Delhi [India], July 8 (ANI): Glenmark Pharmaceuticals will be conducting a Phase III trial on a nasal spray, which it claims to be effective in the treatment of COVID-19.
New Delhi [India], June 22 (ANI): The Drugs Controller General of India (DCGI) is likely to approve Phase III trial data of Covaxin on Tuesday, sources said.
New Delhi [India], June 22 (ANI): Bharat Biotech's Covaxin has shown 77.8 per cent efficacy after the Subject Expert Committee (SEC) under the drug regulator reviewed its Phase III trials data on Tuesday, according to sources.
New Delhi [India], June 22 (ANI): The Subject Expert Committee (SEC) under the drug regulator will discuss reviewing the Phase III data of Bharat Biotech's Covaxin on Tuesday.
New Delhi [India], June 21 (ANI): The Hyderabad-based COVID vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin to Drugs Controller General of India (DCGI) over the weekend, according to government sources.
New Delhi [India], June 7 (ANI): Indian Renewable Energy Development Agency Limited (IREDA), a PSU under the Ministry of New and Renewable Energy (MNRE), has extended the bid submission date to June 15 for implementation of the Central Public Sector Undertaking (CPSU) scheme phase-II for set